Ibex Medical Analytics & Institut Curie (Curie Cancer Carnot Institute) partner to improve AI-powered breast cancer detection

12 2020
Les Carnot et les entreprises

Institut Curie (Curie Cancer Carnot Insitute) and Ibex Medical Analytics, a pioneer in artificial intelligence based cancer diagnostics, announce a research partnership aimed at improving diagnosis of breast cancer with Artificial Intelligence

This research partnership, the first of its kind, will include a rich dataset of breast biopsy slides, digitized using a digital pathology scanner and analyzed for cancer detection by Ibex’s Galen™ Breast solution. Independently, multiple pathologists from Institut Curie (Curie Cancer Carnot Insitute) will diagnose the slides, followed by blinded analysis of the AI-solution’s performance. Galen Breast - the first AI solution used for detection of breast cancer in pathology - was developed utilizing state-of-the-art AI and machine learning techniques and trained on hundreds of thousands of image samples.

This partnership is, once again, indicative of Institut Curie's partnership strategy, as outlines Amaury Martin, PhD, head of Technology Transfer Office at Institut Curie and head of Carnot Curie Cancer: 
"This collaboration illustrates Institut Curie's approach to partnership-based research, combining the expertise of clinicians with the know-how of an innovation-driven technology company. It illustrates our commitment to play a major role in the development of artificial intelligence approaches applied to personalized medicine."